These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 20869878)
1. Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine. Yan W; Chen WC; Liu Z; Huang L Cytokine; 2010 Dec; 52(3):238-44. PubMed ID: 20869878 [TBL] [Abstract][Full Text] [Related]
2. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Do Y; Hegde VL; Nagarkatti PS; Nagarkatti M Cancer Res; 2004 Sep; 64(18):6756-65. PubMed ID: 15374994 [TBL] [Abstract][Full Text] [Related]
3. Precursor frequency analysis of bryostatin activated lymphocytes. Fleming MD; Barrett SK; Bear HD J Surg Res; 1994 Jul; 57(1):74-9. PubMed ID: 8041153 [TBL] [Abstract][Full Text] [Related]
4. [Dendritic cells present particulate E7 protein of human papillomavirus and induce strong immunity]. Li J; Gao HQ; Zhao CL; Li LZ; Ji CY; Hou M; Plebaski M Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):932-6. PubMed ID: 15329282 [TBL] [Abstract][Full Text] [Related]
5. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754 [TBL] [Abstract][Full Text] [Related]
6. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947 [TBL] [Abstract][Full Text] [Related]
7. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. Yan W; Chen W; Huang L J Control Release; 2008 Aug; 130(1):22-8. PubMed ID: 18554742 [TBL] [Abstract][Full Text] [Related]
8. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Yan W; Chen W; Huang L Mol Immunol; 2007 Jul; 44(15):3672-81. PubMed ID: 17521728 [TBL] [Abstract][Full Text] [Related]
10. Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. Ariza ME; Ramakrishnan R; Singh NP; Chauhan A; Nagarkatti PS; Nagarkatti M J Biol Chem; 2011 Jan; 286(1):24-34. PubMed ID: 21036898 [TBL] [Abstract][Full Text] [Related]
11. Bryostatin-1 and IFN-gamma synergize for the expression of the inducible nitric oxide synthase gene and for nitric oxide production in murine macrophages. Taylor LS; Cox GW; Melillo G; Bosco MC; Espinoza-Delgado I Cancer Res; 1997 Jun; 57(12):2468-73. PubMed ID: 9192827 [TBL] [Abstract][Full Text] [Related]
12. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Dell K; Klein C; Gissmann L Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528 [TBL] [Abstract][Full Text] [Related]
13. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074 [TBL] [Abstract][Full Text] [Related]
14. Response of Jurkat T cells to phorbol ester and bryostatin. Development of sublines with distinct functional responses and changes in protein kinase C activity. Levine BL; May WS; Tyler PG; Hess AD J Immunol; 1991 Nov; 147(10):3474-81. PubMed ID: 1834742 [TBL] [Abstract][Full Text] [Related]
16. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590 [TBL] [Abstract][Full Text] [Related]
17. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Fernando GJ; Stewart TJ; Tindle RW; Frazer IH J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239 [TBL] [Abstract][Full Text] [Related]
18. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041 [TBL] [Abstract][Full Text] [Related]
19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 acts synergistically with interleukin-1 alpha to induce secretion of G-CSF and other cytokines from marrow stromal cells. Lilly M; Vo K; Le T; Takahashi G Exp Hematol; 1996 Apr; 24(5):613-21. PubMed ID: 8605966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]